SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurocrine Biosciences (NBIX)
An SI Board Since July 1996
Posts SubjectMarks Bans Symbol
1834 74 0 NBIX
Emcee:  Billy Dunn Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1059As everyone seems to be hanging out on the NBIX thread today, Happy Christmas tnigel bates-12/20/2002
1058<i>Six to 12 months, for now. New family member coming in.</i> Badkeokalani'nui-12/20/2002
1057<i>Anybody else (4%) remember it (4%) that way (4%)???</i> That maknigel bates-12/20/2002
1056<<Back in late 1999 when I was still a biotech neophyte, Rick told me to bJim Haynes-12/20/2002
1055sheesh!! Anybody else (4%) remember it (4%) that way (4%)???scaram(o)uche-12/20/2002
1054>> Rick told me to buy more NBIX << The way I remember it, I said &scaram(o)uche-12/20/2002
1053Back in late 1999 when I was still a biotech neophyte, Rick told me to buy more Biomaven-12/20/2002
1052"SSB raises NBIX to "in-line"... LOL Didn't Solly have it as quidditch-12/20/2002
1051Salomon raises NBIX to "in-line" from underperform. Insight! (eom)scaram(o)uche-12/20/2002
1050>> BAS is estimating 22.5% royalties. << Yeah, but they got that frscaram(o)uche-12/20/2002
1049I think the long patent life of indiplon can't be ignored in the equation. Erkrw-12/20/2002
1048Harry, <<But--if Pfizer "needed this insomnia deal (drug)", my Miljenko Zuanic-12/20/2002
1047Harry: >> the end of that whole ballyhooed GABA collaboration << ascaram(o)uche-12/19/2002
1046$400M in payments, pfe pays all clinical costs and the vast majority of marketinrkrw-12/19/2002
1045Miljenko: I don't claim to know any more about Estorra's characterisicsNeuroInvestment-12/19/2002
1044>>New family member coming in<< Congrats! Hope everything goes wellfred hayes-12/19/2002
1043OT: <<Geeeeeeze, I sure hope that you mean "through the holiday seasMiljenko Zuanic-12/19/2002
1042Harry, So far what I know about Estorra is that they have problem with elderly Miljenko Zuanic-12/19/2002
1041I realize this will seem simplistic but: Pfizer undoubtedly ran DD on both EstorNeuroInvestment-12/19/2002
1040ps -- I know I received some very good responses on this very subject awhile bacfred hayes-12/19/2002
1039>>Wish that there were more data on finance-royalty.<< Amen. That&#fred hayes-12/19/2002
1038>> NBIX move is toward cash preservation, so they can move forward other pscaram(o)uche-12/19/2002
1037Very nice deal for NBIX and strong endorsement for Indiplon. Actually , PFE as lMiljenko Zuanic-12/19/2002
1036I think they're going to push for profitability post indiplon approval and mrkrw-12/19/2002
1035<i>Now the question is of course. How are they going to use all these fundnigel bates-12/19/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News